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A B S T R A C T
Background: Issues related to menopausal symptoms are very complicated in terms of experience, severity, and dynamics 
of the symptoms. Studies have shown that these symptoms vary among individuals depending on the menopausal stage, 
ethnicity, geographical location, and other factors. Menopause Rating Scale (MRS)  is an effective tool to assess the severity of 
these symptoms. Aim: This study was done to compare the frequency and severity of menopausal symptoms during peri‑ and 
postmenopause using the MRS. Subjects and Methods: Ninety‑two perimenopausal women and 95 postmenopausal women 
who attended Gynecology out patient department ( OPD) for treatment of menopausal complaints were assessed using the 
MRS questionnaire before starting therapy. Informed consent and ethics committee clearance was obtained prior to the 
study. Response was recorded and statistical analysis was done using Statistical Package for Social Sciences (SPSS) software 
version 17.0 (SPSS Inc, Chicago, IL, USA). Result: The mean total MRS score was comparable in both the groups. The mean 
psychological  score was  significantly  higher  in  perimenopausal  group  in  comparison  to  postmenopausal  group  (P<0.01). 
The mean urogenital score was higher in postmenopausal women (P < 0.001). Conclusion: Fatigue, depression, anxiety, 
hot flashes, and sexual disturbances were  the common symptoms  that appeared first during  the perimenopausal phase. 
As the age advanced and women progressed in the postmenopausal stage, the psychological symptoms of depression, 
irritability, and sleep disturbances decreased; while the urogenital symptoms, fatigue, and generalized body ache became 
more prominent.
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INTRODUCTION
Menopause is a significant stage marking the end of 
a woman’s reproductive life. Although this process is 
physiological, it is plagued by wide range of discomforting 
features which affects their quality of life. These symptoms 
includes years of hot flashes associated with episodes of 
sweating; sleep disturbances; joint pains; and urogenital 
symptoms such as decrease in libido, dyspareunia, and 
bladder incontinence.[1‑3] These symptoms are primarily due 
to alteration in the hormonal levels, particularly estrogen; 
which in turn is caused by aging of the ovaries.[4‑6]
Studies have shown that the frequency of these symptoms 
and their stability varies. Some occur frequently during 
perimenopause, while others increase progressively from 
peri‑ to postmenopause. Hence, the issues related to 
menopause are very complicated in terms of experience, 
severity, and dynamics of the symptoms.[7‑10]
Lower age of menopause in India compared to the West 
along with increased life expectancy has resulted in a woman 
today spending almost a third of her life in menopause and 
that too with distressing clinical problems.[11‑15] Common 
menopausal symptoms among Indian women have been 
identified, but no study describes these symptoms in terms 
of both frequency and severity. This is necessary to provide 
the best therapy to manage these symptoms. This study 
was aimed to compare the baseline menopausal symptoms 
of perimenopausal and postmenopausal women seeking 
treatment for menopausal complains in tertiary care 
hospital using the Menopause Rating Scale (MRS), which is 
an internationally accepted tool for this purpose.[16‑18]
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SUBJECTS AND METHODS
Study design
This questionnaire‑based study was carried out at a tertiary 
care hospital in Patna on patients attending Gynecology 
outpatient department (OPD) for treatment of menopausal 
complains. The study was approved by the Institutional Ethics 
Committee and consent was obtained from the patients to 
participate. The study was carried out from October 2012 
to October 2013. A total of 187 patients between 40 and 
65 years of age were randomly selected from those who 
had reported to the OPD with complaints of menopausal 
symptoms. Of these 92 were perimenopausal and 95 were 
postmenopausal according to the Stages of Reproductive 
Aging Workshop (STRAW) +10 criteria.[19] Patients with 
undiagnosed vaginal bleeding, cardiac disease, liver disorder, 
diabetes mellitus, breast tumor, or other malignancies; 
history of stroke or transient ischemic attack; and history of 
hormonal treatment or soybean derived products in previous 
12 months were excluded from the study.
Instrument and data collection
The pretested questionnaire consisted of three sections: 
A, B, and C. Section A consisted of sociodemographic data 
which included age, marital status, religion, educational, 
and occupational background. Section B dealt with detailed 
menstrual history and included assessment of menopausal 
status of the patient according to the STRAW + 10 
classification which divided menopausal staging into: 
Postmenopausal (no menstrual bleeding in the last 
12 months);  late perimenopausal  (amenorrhea ≥60 days); 
and early perimenopausal (irregular menses without 
skipping cycles and more than 7 day difference in length of 
consecutive cycles).[19]
The late and early perimenopausal patients were clubbed 
as the perimenopausal group for ease of statistical analysis.
In section C, the English version of the MRS questionnaire 
was used as a tool for assessing menopausal symptoms. 
The MRS questionnaire includes 11 symptoms on a scoring 
scale from “0” (none) to “4” (very severe symptoms). The 
symptoms were further grouped into three subscales: 
somatic, psychological, and urogenital. The English version 
of MRS which is formally validated scale according to 
the requirements for quality of life instrument was used in 
the study. As most of the participants did not know English, 
the questionnaire was administered by face‑to‑face interview 
in the local language by a dedicated postgraduate student. 
Patients answering mild and moderate were grouped as 
one and those answering severe to very severe were also 
grouped together while calculating the prevalence. This 
was done to eliminate any bias while choosing the best 
response.
Statistical analysis
Data was analyzed using Statistical Package for Social 
Sciences (SPSS) software version 17.0 (SPSS Inc, Chicago, 
IL, USA). Results are presented as number (percentage) 
and mean ± standard deviation wherever appropriate. 
Chi‑square test was applied to compare the frequency and 
severity of symptoms among the peri‑ and postmenopausal 
group. P < 0.05 was considered as the cut‑off value for 
significance.
RESULT
The mean age of the perimenopausal group was 
43.45 (2.02) years and that of postmenopausal group 
was 48.52 (2.27) years. Among the postmenopausal 
women, the mean age of menopause observed in our 
study was 45.29 (2.17) years. The frequency and severity 
of menopausal symptoms experienced by the peri‑and 
postmenopausal women, respectively as assessed by MRS is 
depicted in Table 1. Most of the women belonged to middle 
socioeconomic group and had almost similar educational 
background, hence it did not significantly affect the 
difference in their responses.
The mean total response score of the perimenopausal group 
was 21.4 (5.11) and that of the postmenopausal group was 
20.01 (3.99) [Figure 1]. The mean score for somatic subscale 
and psychological scale was higher in perimenopausal 
women in comparison with postmenopausal women. 
The increase in psychological subscale was statistically 
significant (P<0.01). However, the mean score for 
urogenital subscale was significantly higher (P < 0.001) in 
postmenopausal women [Figure 2]. Reliability test of the 
MRS questionnaire responses yielded Cronbach’s alpha of 
the somatic subscale 0.740, psychological subscale 0.718, 
and urogenital subscale 0.718. These scores indicate that 
the response were reliable.
DISCUSSION
Menopause is characterized by an estrogen deficient state 
and is often met with fear by many women.[20] As many 
organs of the body are sensitive to estrogen, a reduction 
in estrogen level gives rise to a number of physical, 
psychological, and sexual changes.[21] Studies have shown 
that the frequency of the symptoms varies over time. 
Some happen frequently in the perimenopause and 
decrease over time, while others increase progressively 
from perimenopause to postmenopause and become more 
severe towards the end of life.[7‑10]
Besides the menopausal status, ethnic variations also affect 
the prevalence and severity of menopausal symptoms.[22,23] 
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Common menopausal symptoms in India vary when compared 
to the West. There are variations within different regions 
of the country.[16‑18] These diversities occur because women 
experience reductions in estrogen levels in a wide variety of 
ways with greater interindividual variation.[23,24]
The mean age at menopause for the postmenopausal group 
observed in our study was 45.29 (2.17) years, which is lower 
than the mean age at menopause in Caucasians, but it was 
within the normal range for the Indian population.[12]
This study was undertaken to describe the menopausal 
symptoms in terms of prevalence and severity in the 
treatment seeking women. The assessment tool used 
in our study was the MRS, which is widely tested and 
accepted internationally.[18] The English version of the MRS 
questionnaire was used. Although it is a self‑administered 
questionnaire, the questions were translated to the patients 
in the local language and correct response was recorded. This 
was done because majority of the patients did not understand 
English. MRS is composed of 11 most commonly experienced 
symptoms and each symptom is given a score from 0 (none) to 
4 (very severe). The symptoms are further grouped into three 
subscales. The somatic subscale includes scores of hot flashes, 
heart discomfort, sleep problems, and joint and muscular 
discomfort. The psychological subscale adds up scores of 
depressive mood, irritability, anxiety, and physical and mental 
exhaustion. Sexual problems, bladder problems, and dryness 
of vagina are included in the urogenital subscale.[16‑18]
The mean total score of the symptoms in both the groups 
were comparable at 21.4 (5.11) and 20.03 (3.99) for peri‑ and 
postmenopausal, respectively and there was no significant 
difference between the total scores of the subscales.
Somatic subscale
In the present study, 112 (40.1%) women reported 
experiencing episodes of hot flashes, sweating, and/or 
night sweats in the preceding 4 weeks. Prevalence of 
vasomotor symptoms shows wide variation throughout the 
world. Studies in the Western population report a higher 
prevalence up to 75%, while a study in Malaysia reported a 
prevalence (41.6%) similar to our study.[7‑11,22] Even in India, 
there are wide variations in prevalence of hot flashes during 
menopause in different regions. Sharma et al., reported 
a higher prevalence (53.86%) of vasomotor symptoms in a 
study done in Northern India, while Shah et al., had reported 
only 19% of women in Mumbai complaining of hot flashes.[13‑15]
Table 1: Frequency and severity of menopausal symptoms among the perimenopausal (n=92) and postmenopausal 
women (n=95) on the menopause rating scale
Menopausal symptoms Perimenopause (n=92) (%) Postmenopause (n=95) (%)
No symptom Mild to moderate Severe to very severe No symptom Mild to moderate Severe to very severe
Somatic
Hot flashes 31 (33.70) 33 (35.87) 28 (30.43) 44 (46.32) 48 (50.53) 3 (3.16)
Cardiac symptoms 28 (30.43) 58 (63.04) 6 (6.52) 22 (23.16) 67 (70.53) 6 (6.32)
Sleep disturbances 42 (45.65) 38 (41.30) 12 (13.04) 52 (54.74) 43 (45.26) 0
Joint and muscle discomfort 0 49 (53.26) 43 (46.74) 0 9 (9.47) 86 (90.53)
Psychological
Depression 6 (6.52) 71 (77.17) 15 (16.30) 58 (61.05) 21 (22.11) 16 (16.84)
Irritability 0 70 (76.09) 22 (23.91) 22 (23.16) 67 (70.53) 6 (6.32)
Anxiety 3 (3.26) 65 (70.65) 24 (26.09) 12 (12.63) 83 (87.37) 0
Physical and mental exhaustion 0 12 (13.04) 80 (86.96) 0 19 (20) 76 (80)
Urogenital
Sexual problems 0 34 (36.96) 58 (63.04) 0 12 (12.63) 83 (87.37)
Bladder problems 31 (33.70) 55 (59.78) 6 (6.52) 13 (13.68) 60 (63.16) 22 (23.16)
Vaginal dryness 0 74 (80.43) 18 (19.57) 0 9 (9.47) 86 (90.53)
Figure 1: Mean total score of peri‑and postmenopausal women on MRS. 
MRS = Menopause Rating Scale
Figure 2: Mean score of subscales of peri‑and postmenopausal women 
on MRS
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Among the 92 perimenopausal women interviewed, 61 
subjects (66.3%) reported experiencing episodes of hot flashes 
and/or nightsweats and 28 (35.87%) had severe to very severe 
symptoms. Though 46 postmenopausal women (52.63%) still 
reported hot flashes in the past 4 weeks, these were mostly 
mild to moderate in nature. Similar observations were 
made in the Menopause Epidemiology (MEPI) study. They 
reported that 79% of perimenopausal women and 65% of 
postmenopausal women experienced hot flashes.[9] The data 
by Study of Women’s Health Across the Nation (SWAN) also 
indicated that hot flushes were more frequently reported by 
women in the late perimenopause.[25]
Hot flashes are believed to result from the brain’s response 
to diminished estrogens and estrogen fluctuations that 
occur during the menopausal transition. With time as 
the fluctuations decrease, so does the severity of the hot 
flashes. Besides hormone levels, ethnicity, climate, diet, 
lifestyle, smoking, and their attitude towards menopause 
also affect the prevalence of vasomotor symptoms.[20‑26]
Ninety‑three women (49.73%) in our study reported that they 
had sleep problems such as difficulty in falling asleep, waking 
up through the night, or waking up early. The frequency 
of sleep disturbances were comparable between the two 
groups, though they were more severe in the perimenopausal 
group compared to the postmenopausal group. But this was 
statistically not significant. These findings were found to 
correspond to findings done in other studies in Indian, Asian, 
as well as Caucasian women.[3,8,13,27] The Medical Research 
Council National Survey of Health and Development (NSHD) 
identified that menopausal transition and its associated 
symptoms especially night sweats were associated with 
trouble initiating sleep and sleep fragmentation. To add to this, 
sleep disturbances may occur independently of menopause in 
postmenopausal women as nocturia, depression and stress 
increase with age and may disturb sleep.[28]
All the women interviewed in our study complained of 
rheumatic complaints like muscle and joint pains. While only 
46.74% of perimenopausal women had severe to very severe 
symptoms, it rose markedly to 90.53% women reporting 
such severity in the postmenopausal group. This statistically 
significant (P < 0.001) increase in severity can be attributed 
to worsening of menopause‑linked osteoporosis. In similar 
demographic studies, joint pains and body ache was found 
to be the commonest menopausal complain in the Indian 
population unlike the West.[12‑15,29] This has been attributed 
to poor diet and low calcium intake by women in the youth 
and lack of physical exercise.[12]
Psychological subscale
Perimenopausal women had 35% higher psychological 
score than postmenopausal women indicating higher 
frequency and severity of symptoms (P < 0.001). This 
decrease in symptom is attributed to the decrease in 
the fluctuation of estrogen levels. The importance of 
estrogen in cognition has been demonstrated by Jacob 
and colleagues.[30] The most consistent symptom in both 
the groups was physical and mental exhaustion, but the 
severity varied. It was observed that 80 perimenopausal 
women (86.96%) complained of severe to very severe 
symptoms as opposed to 76 postmenopausal women (80%). 
Physical and mental exhaustion was also found to be one of 
the commonest findings in other studies done in the Indian 
population.[11,13,14]
It has been suggested that during a hot flush, blood flow 
decreases to the hippocampus, possibly impairing memory 
and cognition.[31,32] The severity of the symptoms of irritability, 
anxiety and depression also decreased with progressing 
age. Besides fluctuating estrogen levels, another reason 
for depression and anxiety could be apprehension towards 
menopause. The Melbourne Women’s Midlife Health 
Project carried out a large‑scale study, the results of which 
indicated that depression scores were higher for women 
who were in the menopause transition stage (i. e., had not 
reached final menstrual period) or who had experienced 
surgical menopause.[33]
Urogenital subscale
Postmenopausal women had 28% higher urogenital score 
than perimenopausal women (P = 0.008). As the frequency 
of symptom was similar in both the groups, the higher score 
of urogenital scale in postmenopausal women was attributed 
to more severe symptoms among them compared to the 
perimenopausal women. Similar distribution of urogenital 
symptoms was also documented by other studies.[3,8,11]
All the women in our study reported a decrease in libido, 
sexual activity and satisfaction. Seventy percent of 
perimenopausal women also complained of having difficulty 
in urination, increased frequency, and bladder incontinence. 
The same was reported by 87% of postmenopausal women. 
However, bladder problems were more troublesome among 
the postmenopausal women with 23.1% reporting severe to 
very severe symptoms compared to 6.52% perimenopausal 
women with similar severity. 90.53% of the postmenopausal 
women reported severe to very severe vaginal dryness 
compared to 19.57% in the perimenopausal group.
As the women progress in postmenopausal age, estrogen 
levels further falls and it results in vaginal atrophy, dryness, 
and other urogenital symptoms. Changes in the vaginal 
environment after menopause predisposes to urinary tract 
infection (UTI). Recurrent UTI in postmenopausal women 
are associated with urinary incontinence, cystocele, and 
increased post‑void residual volume.
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Increasing awareness, lower age of menopause in India, and 
the added burden of surgical menopause has made the woman 
seek therapy for a quality life. Healthcare providers need to 
tailor the therapy according to the most prominent complaint. 
Perimenopausal women with prominent vasomotor symptoms 
and psychological symptoms are most likely to benefit from 
systemic hormone replacement therapy (HRT).[2] Other 
alternative therapies have also been tried for the classical 
presentation of vasomotor symptoms with some success. 
These alternative therapies are most likely to succeed in 
perimenopausal women instead of postmenopausal women in 
whom hot flashes are not of much concern. The main concern 
of postmenopausal women is the urogenital problems for 
which local estrogen cream is the most judicious therapy. 
Also, in postmenopausal women, worsening joint and muscle 
pain deserves special attention from the healthcare provider.
The limitation of our study was small sample size. Moreover, 
the study was done in patients with symptoms severe 
enough to warrant treatment. Thus, the result cannot be 
extrapolated to the population at large. The results are 
only to guide in selecting the best form of therapy. MRS 
questionnaire is a self‑administered questionnaire, but was 
administered by face‑to‑face interview in the local language. 
Some bias is to be expected due to this also.
CONCLUSION
During menopausal transition there are a lot of fluctuations 
in the hormone levels (especially estrogen) and thus women 
experience many symptoms and conditions. However, the 
influence of this fluctuation varies from one woman to 
another. The present study using the MRS showed that the 
mean age of menopause was 45.29 (2.17) years. Study of 
the 11 symptoms on the MRS found that these symptoms 
were more common and severe during the perimenopausal 
phase. Fatigue, depression, anxiety, hot flashes, and sexual 
disturbances were the common symptoms that appeared 
first during the menopausal transition. As the age advanced 
and women progressed in the postmenopausal stage, the 
psychological symptoms of depression, irritability, and sleep 
disturbances decreased; while the urogenital symptoms, 
fatigue, and generalized body ache become more prominent.
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